Claudia Diamonte

2.4k total citations
18 papers, 353 citations indexed

About

Claudia Diamonte is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Claudia Diamonte has authored 18 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 4 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Claudia Diamonte's work include CAR-T cell therapy research (17 papers), Biosimilars and Bioanalytical Methods (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Claudia Diamonte is often cited by papers focused on CAR-T cell therapy research (17 papers), Biosimilars and Bioanalytical Methods (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Claudia Diamonte collaborates with scholars based in United States, Poland and United Kingdom. Claudia Diamonte's co-authors include Elizabeth Halton, Renier J. Brentjens, Isabelle Rivière, Michel Sadelain, Brigitte Sénéchal, John Pineda, Xiuyan Wang, Jae H. Park, Yvette Bernal and Roisin E. O’Cearbhaill and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Claudia Diamonte

18 papers receiving 349 citations

Peers

Claudia Diamonte
Xia Han United States
Minnal Gupta United States
Erin Mullane United States
Jolanta Stefanski United States
Edward Waldron United States
Sharon Yim United States
Zhuojun Ling China
Jiazhen Cui China
Vania Aikawa United States
Elizabeth Halton United States
Xia Han United States
Claudia Diamonte
Citations per year, relative to Claudia Diamonte Claudia Diamonte (= 1×) peers Xia Han

Countries citing papers authored by Claudia Diamonte

Since Specialization
Citations

This map shows the geographic impact of Claudia Diamonte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Diamonte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Diamonte more than expected).

Fields of papers citing papers by Claudia Diamonte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Diamonte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Diamonte. The network helps show where Claudia Diamonte may publish in the future.

Co-authorship network of co-authors of Claudia Diamonte

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Diamonte. A scholar is included among the top collaborators of Claudia Diamonte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Diamonte. Claudia Diamonte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2021). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 35(11). 3268–3271. 26 indexed citations
2.
Wudhikarn, Kitsada, Jessica Flynn, Isabelle Rivière, et al.. (2021). Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 138(7). 531–543. 47 indexed citations
3.
Jain, Tania, Andrea Knežević, Martina Pennisi, et al.. (2020). Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies. Biology of Blood and Marrow Transplantation. 26(3). S63–S64. 1 indexed citations
4.
Park, Jae H., Isabelle Rivière, Devanjan Sikder, et al.. (2020). A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 136(Supplement 1). 43–44. 2 indexed citations
5.
6.
Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Research. 79(13_Supplement). CT036–CT036. 44 indexed citations
7.
Smith, Melody, Eric R. Littmann, John Slingerland, et al.. (2019). Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy. Biology of Blood and Marrow Transplantation. 25(3). S177–S177. 9 indexed citations
8.
Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Clinical Trials. CT036–CT036. 8 indexed citations
9.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2019). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL.. Journal of Clinical Oncology. 37(15_suppl). 2520–2520. 9 indexed citations
10.
Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.. Journal of Clinical Oncology. 37(15_suppl). 2511–2511. 74 indexed citations
11.
12.
Santomasso, Bianca, Jae Hong Park, Isabelle Rivière, et al.. (2018). Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008). Neurology. 90(15_supplement). 3 indexed citations
13.
Park, Jae H., Maria Lia Palomba, Connie Lee Batlevi, et al.. (2018). A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation. Blood. 132(Supplement 1). 224–224. 37 indexed citations
14.
Halton, Elizabeth, et al.. (2017). Developing Infrastructure: Managing Patients With Cancer Undergoing CAR T-Cell Therapy. Clinical journal of oncology nursing. 21(2). 35–40. 6 indexed citations
15.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2017). Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.. Journal of Clinical Oncology. 35(15_suppl). 7008–7008. 13 indexed citations
16.
Park, Jae Hong, Bianca Santomasso, Isabelle Rivière, et al.. (2017). Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.. Journal of Clinical Oncology. 35(15_suppl). 7024–7024. 20 indexed citations
17.
Santomasso, Bianca, Jae Hong Park, Isabelle Rivière, et al.. (2017). Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells.. Journal of Clinical Oncology. 35(15_suppl). 3019–3019. 18 indexed citations
18.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2017). A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.. Journal of Clinical Oncology. 35(15_suppl). TPS7568–TPS7568. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xia Han Breakdown of academic impact, for papers by Minnal Gupta Breakdown of academic impact, for papers by Erin Mullane Breakdown of academic impact, for papers by Jolanta Stefanski Breakdown of academic impact, for papers by Edward Waldron Breakdown of academic impact, for papers by Sharon Yim Breakdown of academic impact, for papers by Zhuojun Ling Breakdown of academic impact, for papers by Jiazhen Cui Breakdown of academic impact, for papers by Vania Aikawa Breakdown of academic impact, for papers by Elizabeth Halton
Rankless by CCL
2026